About Imagion Biosystems
Imagion’s MagSense® technology has the potential to provide more specific and sensitive detection for cancer than current imaging technologies. By using tiny magnetic nanoparticles to identify tumors, our MagSense® technology does not require use of radioactivity, making it a safer alternative for non- invasive detection.
Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

Latest News and Events
Quarterly Activity Report and Appendix 4C for 31 Mar 2022
April 28, 2022
Imagion has released the Quarterly Activity Report and Appendix 4C for the…
Imagion Biosystems April 2022 Investor Newsletter
April 14, 2022
We are pleased to provide our investors with our April 2022 Investor…
Employee Spotlight: Dan Inglese, Research Associate
April 12, 2022
Highlighting our dedicated employees who bring both their experience…
Welcome TJ Stalvey
April 8, 2022
We are pleased to welcome our latest Imagioneer to the Imagion Bio team! As we…
MagSense® HER2 Breast Cancer First-in-human Study Progress Update
March 17, 2022
Imagion Biosystems Limited (ASX: IBX) is pleased to provide an update on the…
Imagion Biosystems 2021 Full Year Results
February 24, 2022
Imagion Biosystems has released its Annual Report for the year ended 31…
Quarterly Activity Report and Appendix 4C for 31 December 2021
January 28, 2022
Imagion has released the Quarterly Activity Report and Appendix 4C for the…
Imagion Bio at The Edison Open House: Global Healthcare 2022
January 17, 2022
Our CEO, Bob Proulx, connected with the Edison Group during their Global…
Application for quotation of +securities
January 6, 2022
The document "Application for quotation of +securities" was lodged with ASX on…
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
January 6, 2022
The document "Notice Pursuant to Section 708A(5)(e) of the Corporations Act…
Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems
December 21, 2021
Tim Boreham revisits Imagion Biosystems' potential in this 5-1/2 page article…
Notification of Issue, Conversion of Payment up of Unquoted Equity Securities
December 16, 2021
The document "Notification of Issue, Conversion of Payment up of Unquoted…
Remuneration Update and Employee Equity Incentives
December 16, 2021
The document "Remuneration Update and Employee Equity Incentives" was lodged…
Imagion Biosystems December 2021 Investor Newsletter
December 16, 2021
We are pleased to provide our investors with our December 2021 Investor…
Employee Spotlight: Carmen Soikowski, Director of Operations
December 13, 2021
Highlighting our dedicated employees who bring both their experience and…
IBXO Options Exercise Complete
December 1, 2021
Imagion Biosystems is pleased to advise that it has now received the full $4.8…
Appendix 2A — Application for Quotation of +Securities
December 1, 2021
The following Appendix 2A was announced via ASX on 1 Dec 2021. Please click to…
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
December 1, 2021
The following cleansing notice was lodged with ASX on December 1, 2021: Imagion…
Magnetic Nanoparticles as Imaging Agents Presentation at the 2021 VBIC Meeting
November 27, 2021
As a sponsor of the 2021 Annual VBIC Network Meeting, Imagion Biosystems'…
Appendix 2A Application for quotation of +securities
November 25, 2021
The following Appendix 2A was announced via ASX on 25 Nov 2021. Please click to…
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
November 25, 2021
The following cleansing notice was lodged with ASX on November 25, 2021:…
Corporategovernance
Imagion Biosystems and its Board of Directors is committed to maintain high levels of integrity and ethical standards in the way we conduct our business and in our corporate governance.
The Board of Directors is composed, chiefly, of non-executive directors with the Chairman having been elected by the full Board. The company is small, and accordingly, the Board has adopted those policies it deems prudent to protect the interests of our shareholders without being overly burdensome on the company.
Investor services
Investors seeking information regarding their shareholding or dividends or wishing to advise of a change of address should contact Boardroom Pty Limited at:
Boardroom Pty Limited
Level 12, 225 George Street,
Sydney, NSW, 2000
Telephone: (02) 9290 9600 Facsimile: (02) 9279 0664 or
Visit the online service at www.boardroomlimited.com.au
Boardroom Pty Limited has an online service for investors called InvestorServe. This enables investors to make online changes, view balances and transaction history, as well as obtain information about recent dividend payments and download various forms to assist in the management of their holding.
Questions?
Reach the Investor Relations department by emailing investor@imagionbio.com, and we’ll get back to you.